Dyspro™ Distribution Begins as EVE Targets $20B Dysmenorrhoea Market by 2035
EVE Health Group has begun distributing Dyspro™, a novel cannabinoid-based treatment for dysmenorrhoea and endometriosis, through a national telehealth partnership. This launch targets a significant unmet need in women’s health with a growing global market.
- Dyspro™ manufactured at Australian GMP-certified facility
- Available for prescription through TeleDocs telehealth network
- Targets dysmenorrhoea and endometriosis with large unmet medical needs
- Global treatment market expected to exceed USD 20 billion by 2035
- EVE exploring additional distribution and export opportunities
A New Chapter in Women’s Health
EVE Health Group (ASX – EVE) has reached a pivotal milestone with the commencement of distribution for Dyspro™, its first-in-class cannabinoid-based gummy designed to alleviate symptoms of dysmenorrhoea and endometriosis. Following successful Good Manufacturing Practice (GMP) certification and commercial-scale production in Australia, Dyspro™ is now being dispatched to distribution partners ahead of its official launch.
This development marks a significant step forward in addressing two of the most prevalent and under-treated conditions affecting women globally. Dysmenorrhoea, characterized by painful menstruation, affects a vast majority of women of reproductive age, while endometriosis is a chronic inflammatory disease with substantial personal and economic burdens.
Leveraging Telehealth for Broad Access
EVE has partnered with TeleDocs Clinic, a leading digital health platform, to facilitate nationwide prescribing and dispensing of Dyspro™. This collaboration enables patients to access prescriptions through telehealth consultations, with fulfillment available at over 3,500 pharmacies across Australia. The partnership not only streamlines patient access but also positions Dyspro™ well within the evolving healthcare delivery landscape.
Beyond this initial channel, EVE is actively evaluating additional prescribing and distribution partnerships to diversify access pathways. Such efforts aim to enhance scalability and explore export opportunities, potentially expanding Dyspro™’s reach beyond Australian borders.
Market Potential and Unmet Needs
The market opportunity for Dyspro™ is substantial. Recent studies highlight that 77% of Australian women aged 18–44 experience bothersome menstrual symptoms, with nearly half reporting lost productivity due to these issues. Endometriosis affects up to 14% of women in this demographic, imposing significant healthcare and economic costs.
Globally, the dysmenorrhoea treatment market was valued at USD 10.9 billion in 2024 and is projected to nearly double to USD 20 billion by 2035. Meanwhile, the Australian endometriosis treatment market is forecast to grow at a robust 13% compound annual growth rate through 2030. Dyspro™’s cannabinoid-based formulation offers a novel therapeutic option in this expanding landscape.
Looking Ahead
Dr Stuart Gunzburg, EVE’s Executive Director and Chief Scientific Officer, described the transition from laboratory development to large-scale manufacture and distribution as a “transformational moment” for the company. The focus now shifts to ensuring broad patient access and monitoring early adoption through TeleDocs and other channels under consideration.
As EVE navigates this commercial launch, the company’s ability to capitalize on the growing demand for innovative women’s health solutions will be critical. The success of Dyspro™ could pave the way for further cannabinoid-based therapies in this underserved therapeutic area.
Bottom Line?
EVE’s Dyspro™ launch sets the stage for reshaping women’s health treatment, with market uptake and partnership expansion key to watch.
Questions in the middle?
- How quickly will Dyspro™ gain traction among prescribers and patients through TeleDocs?
- What additional partnerships or export deals might EVE secure to broaden Dyspro™’s reach?
- How will regulatory developments impact the commercial rollout of cannabinoid-based women’s health products?
